Open AccessA20 plays a critical role in the immunoregulatory function of mesenchymal stem cells
Author(s) -
Dang RuiJie,
Yang YanMei,
Zhang Lei,
Cui DianChao,
Hong Bangxing,
Li Ping,
Lin Qiuxia,
Wang Yan,
Wang QiYu,
Xiao Fengjun,
Mao Ning,
Wang Changyong,
Jiang XiaoXia,
Wen Ning
Publication year - 2016
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.12849
Subject(s) - mesenchymal stem cell , microbiology and biotechnology , function (biology) , stem cell , biology , computational biology
Mesenchymal stem cells ( MSC s) possess an immunoregulatory capacity and are a therapeutic target for many inflammation‐related diseases. However, the detailed mechanisms of MSC ‐mediated immunosuppression remain unclear. In this study, we provide new information to partly explain the molecular mechanisms of immunoregulation by MSC s. Specifically, we found that A20 expression was induced in MSC s by inflammatory cytokines. Knockdown of A20 in MSC s resulted in increased proliferation and reduced adipogenesis, and partly reversed the suppressive effect of MSC s on T cell proliferation in vitro and inhibited tumour growth in vivo . Mechanistic studies indicated that knockdown of A20 in MSC s inhibited activation of the p38 mitogen‐activated protein kinase (MAPK) pathway, which potently promoted the production of tumour necrosis factor ( TNF )‐α and inhibited the production of interleukin ( IL )‐10. Collectively, these data reveal a crucial role of A20 in regulating the immunomodulatory activities of MSC s by controlling the expression of TNF ‐α and IL ‐10 in an inflammatory environment. These findings provide novel insights into the pathogenesis of various inflammatory‐associated diseases, and are a new reference for the future development of treatments for such afflictions.